

Testicular (Germ Cell) Cancer Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op
__1st Line __2nd Line __3rd Line __3rd Line+ __Maint

ECOG Performance Status: _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (select all that apply)

Platinum-refractory or resistant? __Yes __No __Not Reported

Seminoma | Stage IS-III A | Primary Therapy

___**BEP:** bleomycin, etoposide (Toposar), and cisplatin

___**EP:** etoposide (Toposar) and cisplatin

Seminoma | Stage IIIB-C | Good and Intermediate Risk | Metastatic Disease

___**BEP:** bleomycin, etoposide (Toposar), and cisplatin*

Nonseminoma | Stage II-III A | Primary Therapy

___**BEP:** bleomycin, etoposide (Toposar), and cisplatin

___**EP:** etoposide (Toposar) and cisplatin

Nonseminoma | Stage IIIB-C | Primary Therapy

___**BEP:** bleomycin, etoposide (Toposar), and cisplatin

Nonseminoma | Adjuvant Therapy after RPLND†

___**EP:** etoposide (Toposar) and cisplatin

*BEP is typically given for 3 cycles in good risk seminoma, and 4 cycles in intermediate risk

†RPLND: Retroperitoneal lymph node dissection

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 4/28/2020 | Effective date: 8/12/2019

Appropriate.Safe.Affordable

© 2020 AIM Specialty Health
9022-0720